Opinion|Videos|July 26, 2024
Less Common Molecular Alterations in pLGG and Testing Recommendations
Author(s)Jason Fangusaro, MD
The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for patient care.
Advertisement
Episodes in this series
- Are there particular considerations depending on the type of BRAF alteration?
Advertisement
Related to this article
MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
3
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
4
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
5